US judge blocks some North Carolina restrictions on abortion pill
By Brendan Pierson (Reuters) - A federal judge has struck down parts of a North Carolina law restricting patients' access to the abortion pill mifepristone, which has become the subject of legal battles nationwide. U.S. District Judge Catherine Eag...
14h ago
Bird flu testing shows more dairy products are safe, US FDA says
By Julie Steenhuysen and Tom Polansek NEW YORK (Reuters) -The U.S. Food and Drug Administration said on Wednesday that preliminary results of additional testing of more dairy products has shown that pasteurization inactivates the bird flu virus. The FD...
14h ago
VP Harris visits Florida as abortion ban limits southern women's options
By Nandita Bose WASHINGTON (Reuters) - U.S. Vice President Kamala Harris visits Florida on Wednesday to denounce the state's six-week abortion ban that takes effect on May 1, and will accuse Republican opponent Donald Trump of being responsible for...
16h ago
US bird flu outbreak spreads to chickens, cattle, raises concerns over human infections
(Reuters) - The outbreak of H5N1 bird flu virus has spread to dairy cows for the first time in the United States, raising concerns about it spreading to humans through the nation's milk supply. Since 2022, bird flu in the United States has infected...
18h ago
UnitedHealth CEO testifies on hack before U.S. Senate and House
By Ahmed Aboulenein WASHINGTON (Reuters) -UnitedHealth CEO Andrew Witty began his first of two scheduled testimonies in front of Congressional panels on Wednesday, answering questions from lawmakers about the recent cyberattack at the company's technol...
18h ago
Amgen investors await weight-loss drug data
By Deena Beasley (Reuters) - Amgen investors eyeing dramatic share price gains for rivals with successful obesity drugs will be focused on any updates the biotech company may provide on its own weight-loss drug candidates when it reports quarterly ...
20h ago
Bio-Techne beats third-quarter estimates on improving demand for biotech products
(Reuters) - Bio-Techne on Wednesday beat third-quarter profit and revenue estimates, helped by better-than-expected demand for its cell and gene therapy products and testing and diagnostic devices. On an adjusted basis, the company posted a profit ...
20h ago
Cencora beats profit estimates on strong demand for costly specialty drugs
(Reuters) - Cencora beat Wall Street estimates for second-quarter profit on Wednesday, driven by robust demand for costly specialty medicines that treat complex diseases such as cancer and rheumatoid arthritis. The drug distributor has been benefit...
20h ago
IDEXX Labs cuts 2024 revenue forecast on lagging vet visits, strong dollar
(Reuters) - IDEXX Laboratories lowered its annual sales forecast after missing quarterly estimates on Wednesday, as the animal diagnostic equipment maker expects a hit from a slowdown in veterinary clinic visits by pet owners and a stronger dollar....
20h ago
J&J advances $6.475 billion settlement of talc cancer lawsuits
By Dietrich Knauth NEW YORK(Reuters) - Johnson & Johnson is moving forward with a $6.475 billion proposed settlement of tens of thousands of lawsuits alleging that its baby powder and other talc products contain asbestos and cause ovarian cancer, t...
21h ago
CVS cuts 2024 profit forecast as insurance unit faces soaring medical costs
(Reuters) -CVS Health Corp slashed its annual profit forecast and missed Wall Street estimates for first-quarter earnings on Wednesday, as elevated demand for non-urgent procedures increased medical costs at its health insurance business. The U.S. heal...
21h ago
Pfizer lifts 2024 profit view on cost cuts, higher COVID vaccine demand
(Reuters) -Pfizer lifted its annual profit forecast on Wednesday, banking on cost cuts and better-than-expected demand for its COVID antiviral treatment and vaccine. The U.S. drugmaker's shares rose nearly 3% before the bell after the company said it e...
21h ago
Denmark to restrict Ozempic, other GLP-1 drugs, to treat type 2 diabetes
COPENHAGEN (Reuters) - Denmark will start putting patients suffering from type 2 diabetes on cheaper drugs before prescribing so-called GLP-1 drugs such as Novo Nordisk's Ozempic, the Danish Medicines Agency said on Wednesday. In 2023, 50% of new p...
21h ago
Arizona Senate expected to vote on 1864 abortion ban repeal
By Brad Brooks (Reuters) - The Arizona Senate is expected to vote on Wednesday on a measure to repeal the state's 1864 ban on abortion, which could go into effect within weeks if not struck down. The Arizona House last week passed the measure after...
21h ago
Optomed Oyj, AEYE Health say portable device to detect eye issues gets FDA nod
(Reuters) - A portable device that detects eye conditions that can cause sight loss in people with conditions such as diabetes has received clearance from the U.S. health regulator, its developers Optomed Oyj and AEYE Health said. "I'm thrilled to ...
21h ago
UK's Smith+Nephew retains annual forecasts despite Q1 revenue miss
(Reuters) - British medical equipment maker Smith+Nephew retained its annual revenue and profit forecasts on Wednesday, despite marginally missing market expectations for first-quarter revenue due to a softness in its advanced wound management segm...
May 01, 2024
Haleon's first-quarter revenue misses expectations
(Reuters) - Consumer healthcare company Haleon's first-quarter revenue missed market estimates on Wednesday, due to retailer destocking in the U.S., and a cool down in demand for cold and flu medication after a surge last year. Revenues stood at 2....
May 01, 2024
Novo Nordisk owner to invest $200 million in quantum computing startups
By Martin Coulter LONDON (Reuters) - Novo Holdings, the controlling shareholder of Danish obesity drugmaker Novo Nordisk, said on Wednesday it plans to invest around $200 million in quantum computing startups. The company, the investment arm of the...
May 01, 2024
GSK raises full-year profit forecast, says first-half will see stronger sales
(Reuters) -GSK raised its full-year profit forecast on Wednesday and said its sales would be higher in the first six months of the year than the second half on the back of strong demand for its common respiratory virus and shingles vaccines. The London...
May 01, 2024
Stryker lifts 2024 profit forecast on strong demand for medical devices, implants
(Adds media packaging code) (Reuters) - Stryker Corp lifted its full-year profit forecast on Tuesday, owing to resilient demand for the company's medical devices and implants. The joint-implant maker now sees its annual profit per share to be betwe...
May 01, 2024
Neurocrine Biosciences' Huntington's disease drug gets FDA approval
By Sruthi Narasimha Chari (Reuters) -The U.S. Food and Drug Administration (FDA) has approved the granule formulation of Neurocrine Biosciences' Ingrezza drug to treat movement disorders associated with Huntington's disease (HD), the company said on Tu...
May 01, 2024
Instant view: Biden administration plans to reclassify marijuana
(Reuters) - The U.S. Justice Department on Tuesday moved to make marijuana use a less serious federal crime, taking a step to reclassify the drug out of a category that includes heroin in a shift that, once completed, would shake up cannabis policy...
Apr 30, 2024
First trial over Zantac cancer claims set to begin in Chicago
By Brendan Pierson (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago. Jury selection began on Tuesday before Judge Daniel Trevino...
Apr 30, 2024
Almost all US hospitals took financial hit from Change hack, AHA says
By Amina Niasse NEW YORK (Reuters) - Almost all U.S. hospitals were hurt financially by the cyberattack on United Health Group's Change Healthcare unit earlier this year, according to a survey from the American Hospital Association (AHA). The AHA s...
Apr 30, 2024
Pot stocks jump as U.S. DOJ moves to reclassify cannabis as a less dangerous drug
(Reuters) - Shares of cannabis companies surged on Tuesday afternoon after the U.S. Department of Justice (DoJ) moved to reclassify marijuana as a less dangerous drug. U.S.-listed shares of Cronos Group, Tilray Brands and Canopy Growth rose between...
Apr 30, 2024